血液病患者侵袭性肺曲霉病如何安全停用抗真菌治疗
本文为叙述性综述,汇总临床试验、观察性研究、生物标志物及影像学证据,探讨血液系统恶性肿瘤患者侵袭性肺曲霉病(IPA)停用抗真菌治疗的考量。作者指出目前缺乏标准化停药标准,停药决策需综合宿主免疫状态、临床稳定性、真菌学标志物(尤其血清半乳甘露聚糖)及影像学,以组合方式评估,并需预设监测与快速响应路径。
要点
- 停药决策应基于宿主免疫恢复、临床稳定、真菌学标志物和影像学的组合评估,不可单凭任一指标。
- 持续免疫抑制患者复发风险高,需权衡延长抗真菌治疗的累积毒性与药物相互作用。
- 停药后应结构化监测,并预设立即重新评估的触发因素及不应停药的情形。
核心结论
- IPA停用抗真菌治疗应成为标准化且个体化的决策,并纳入机构标准化流程中的预设监测与快速响应路径。
- 需开展前瞻性试验比较不同停药策略,以明确最佳疗程,尤其在免疫抑制反复或持续存在时。
研究设计与样本
- 叙述性综述,检索范围涵盖临床试验、观察性研究、生物标志物研究、影像学数据及与IPA治疗反应、复发和抗真菌毒性相关的专家指导。
主要发现
- 治疗成功已有共享定义,但治疗失败、疾病稳定和停药的标准化标准仍缺乏。
- 停药决策依赖对宿主免疫状态与恢复、临床稳定性、真菌学标志物(尤其血清半乳甘露聚糖)及影像学(主要为胸部CT)的个体化评估,[18F]氟脱氧葡萄糖正电子发射断层扫描和新兴生物标志物具有辅助作用。
- 上述所有指标的敏感性均有限,需全面解读,并应作为组合而非独立标准使用。
- 持续免疫抑制患者复发风险较高,需与长期抗真菌治疗的累积毒性和药物相互作用进行权衡。
关键数值与推荐
- 综述提出停用抗真菌治疗的前提条件、停药后的结构化监测、立即重新评估的触发因素以及不应停药的情形。
临床怎么用
- 临床停用IPA抗真菌治疗前应组合评估宿主免疫恢复、临床稳定性、血清半乳甘露聚糖和胸部CT等影像学,不应单独依据任一指标。
- 停药后按预设路径进行结构化监测,并明确立即重新评估的触发因素,同时识别不应停药的情形。
- 对持续免疫抑制患者,需权衡复发风险与延长抗真菌治疗的累积毒性及药物相互作用。
局限性
- 治疗失败、疾病稳定和停药的标准化标准缺乏,现有指标敏感性有限。
- 需前瞻性试验比较停药策略以明确最佳疗程,尤其在免疫抑制反复或持续存在时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment duration in invasive pulmonary aspergillosis (IPA) in patients with haematological malignancies is not well defined through clinical trials and is therefore often driven more by experience than evidence, with implications for outcome, patient quality-of-life, drug toxicity, costs, and antifungal stewardship. OBJECTIVES: To review current evidence and provide expert considerations regarding cessation of antifungal therapy for IPA, and to propose pragmatic criteria and follow-up strategies to guide safe discontinuation and early detection of recurrence. SOURCES: Narrative review of clinical trials, observational and biomarker studies, imaging data, and expert guidance related to IPA treatment response, recurrence, and antifungal toxicity. CONTENT: Shared definitions of treatment success exist, but standardized criteria for treatment failure, stable disease, and stopping therapy are lacking. Decisions to discontinue antifungals rely on individualized assessment of host immune status and recovery, clinical stability, mycological markers (notably serum galactomannan), and imaging findings, primarily chest computed tomography, with adjunctive roles for [18F] Fluorodeoxyglucose Positron Emission Tomography and emerging biomarkers. All of the above have limited sensitivity, require thorough interpretation, and are to be used as a bundle, not as standalone criterion. Our review outlines prerequisites for stopping treatment, structured surveillance after cessation, triggers for immediate re-evaluation, and scenarios in which treatment should not be stopped. Risks of recurrence, particularly in persistently immunocompromised patients, are weighed against cumulative toxicity and drug-drug interactions of prolonged antifungal use. Management options for antifungal toxicity and potential utility of novel antifungal agents are discussed. IMPLICATIONS: Stopping antifungal therapy for IPA should be a standardized and patient-specific decision supported by predefined monitoring and rapid response pathways within standardized institutional procedures. Prospective trials comparing cessation strategies are needed to increase knowledge on optimal duration, in specific during reoccurring or ongoing immunosuppression.
引用
- Stemler J, Sprute R, Koehler P, et al. How to safely discontinue antifungal treatment in invasive pulmonary aspergillosis?-clinical considerations in haematology. Clin Microbiol Infect. 2026. PMID: 41796963. doi:10.1016/j.cmi.2026.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。